Evidence map›Paper›PMID 33187969›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2021

Shorter Treatment-Naïve Leukocyte Telomere Length is Associated with Poorer Overall Survival of Patients with Pancreatic Ductal Adenocarcinoma.

Samuel O Antwi, William R Bamlet, Richard M Cawthon, Kari G Rabe, Brooke R Druliner, Hugues Sicotte, Aminah Jatoi, Amit Mahipal, Lisa A Boardman, Ann L Oberg and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Influence of Cancer Susceptibility Gene Mutations and ABO Blood Group of Pancreatic Cancer Probands on Concomitant Risk to First-Degree Relatives.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Samuel O AntwiDivision of Epidemiology, Mayo Clinic, Jacksonville, Florida. Antwi.samuel@mayo.edu.
William R BamletDivision of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0003-2903-1284
Richard M CawthonDepartment of Human Genetics, University of Utah, Salt Lake City, Utah.ORCID 0000-0001-6073-9112
Kari G RabeDivision of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-7313-1875
Brooke R DrulinerGastroenterology Laboratory, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-0304-8515
Hugues SicotteDivision of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota.
Aminah JatoiDivision of Medical Oncology, Mayo Clinic, Rochester, Minnesota.
Amit MahipalDivision of Medical Oncology, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-1111-8333
Lisa A BoardmanDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-1330-2054
Ann L ObergDivision of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0003-2539-9807
Gloria M PetersenDivision of Epidemiology, Mayo Clinic, Rochester, Minnesota.
Mayo Clinic · USJacksonville College · USUniversity of Utah · US

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3M
Tissue CoreP50CA102701 · NCI · MAYO CLINIC ROCHESTER · PI MUKHOPADHYAY, DEBABRATA · 2004 to 2018
$32.7M
ZESTRIL VS. VERAPAMIL IN THE TREATMENT OF HYPERTENSIONM01RR000585 · NCRR · MAYO CLINIC ROCHESTER · PI RIZZA, ROBERT A. · 1985 to 2006
$30.4M
Institutional Career Development CoreKL2TR002379 · NCATS · MAYO CLINIC ROCHESTER · PI NILUFER ERTEKIN-TANER · 2017 to 2026
$14.9M
Individualizing colorectal cancer patient care using the host and tumor telomere phenotypeR01CA204013 · NCI · MAYO CLINIC ROCHESTER · PI BOARDMAN, LISA ALLYN · 2016 to 2020
$3.2M
Integrated molecular epidemiologic analysis of the one-carbon metabolism pathway and risk of HCCK01CA237875 · NCI · MAYO CLINIC JACKSONVILLE · PI ANTWI, SAMUEL O. · 2020 to 2024
$829k
NCATS NIH HHS KL2 TR002379NCI NIH HHS K01 CA237875NCI NIH HHS P30 CA015083NCI NIH HHS P50 CA102701NCI NIH HHS R01 CA204013NCRR NIH HHS M01 RR000585
6 · The paper itself

Abstract

backgroundCritically shortened telomeres contribute to chromosomal instability and neoplastic transformation and are associated with early death of patients with certain cancer types. Shorter leukocyte telomere length (LTL) has been associated with higher risk for pancreatic ductal adenocarcinoma (PDAC) and might be associated also with survival of patients with PDAC. We investigated the association between treatment-naïve LTL and overall survival of patients with incident PDAC.

methodsThe study included 642 consecutively enrolled PDAC patients in the Mayo Clinic Biospecimen Resource for Pancreas Research. Blood samples were obtained at the time of diagnosis, before the start of cancer treatment, from which LTL was assayed by qRT-PCR. LTL was first modeled as a continuous variable (per-interquartile range decrease in LTL) and then as a categorized variable (short, medium, long). Multivariable-adjusted HRs and 95% confidence intervals (CI) were calculated for overall mortality using Cox proportional hazard models.

resultsShorter treatment-naïve LTL was associated with higher mortality among patients with PDAC (HR

conclusionShorter treatment-naïve LTL is associated with poorer overall survival of patients with incident PDAC. IMPACT: Peripheral blood LTL might be a prognostic marker for PDAC.

Indexed as

Telomere ShorteningAdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, Pancreatic DuctalFemaleHumansMaleMiddle AgedPancreatic NeoplasmsProportional Hazards ModelsProspective StudiesReal-Time Polymerase Chain ReactionRisk AssessmentBiomarkers, Tumor

Identifiers

PMID33187969
PMCPMC7855627
OpenAlexW3103794030

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.